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Introduction
Tobacco use is one of the main risk factors for many chronic illnesses 
including cancer, lung diseases, and cardiovascular diseases, mak-
ing it one of the largest preventable causes of premature death and 
disease across the world. Tobacco kills nearly 6 million people each 
year and this could rise to 8 million by 2030.1
Smoking is particularly prevalent in the population of those in 
treatment or recovery from substance use disorders. Between 74% 
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Abstract
Introduction: The aim was to evaluate the effectiveness of smoking cessation interventions for 
patients with substance use disorders. The secondary aim was to evaluate impact on substance 
use treatment outcomes.
Methods: Randomized controlled trials involving adult smokers, recently or currently receiving 
inpatient or outpatient treatment for substance use disorders were reviewed. Databases, grey lit-
erature, reference lists, and journals were searched for relevant studies between 1990 and August 
2014. Two authors extracted data and assessed quality. The primary outcome was biochemically 
verified continuous abstinence from smoking at 6 or 12 months, secondary outcomes were bio-
chemically verified 7-day point prevalence smoking abstinence (PPA) at 6 or 12 months and sub-
stance use outcomes. Heterogeneity between studies precluded pooled analyses of the data.
Results: Seventeen of 847 publications were included. Five studies reported significant effects on 
smoking cessation: (1) nicotine patches improved continuous abstinence at 6 months; (2) nicotine 
gum improved continuous abstinence at 12 months; (3) counseling, contingency management and 
relapse prevention improved continuous abstinence at 6 and 12 months; (4) cognitive behavioral 
therapy, plus nicotine replacement therapy (NRT), improved PPA at 6 months; and (5) a combina-
tion of bupropion, NRT, counseling and contingency management improved PPA at 6 months. Two 
studies showed some evidence of improved substance use outcomes with the remaining eight 
studies measuring substance use outcomes showing no difference.
Conclusions: NRT, behavioral support, and combination approaches appear to increase smoking 
abstinence in those treated for substance use disorders. Higher quality studies are required to 
strengthen the evidence base.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ 
licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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and 98% of patients with substance use disorders are also smok-
ers.2–6 Many patients with substance use disorders may overcome 
their primary addiction and then die from a tobacco related illness.7 
For example, in a cohort of former alcoholics and patients with drug 
dependence, 51% of deaths were from tobacco related causes.8
Smoking may be seen as beneficial when giving up alcohol or 
drugs,9 for example, through perceptions that it is calming or less-
ens anxiety, but such perceptions are likely due to misattribution 
given smoking relieves nicotine withdrawal.10 In general, smoking 
has been shown to be an ineffective coping strategy and may worsen 
substance use treatment outcomes.11,12
The negative health effects of smoking and the benefits of offering 
smoking cessation to patients with substance use disorders are well 
known but more research is needed to identify successful interven-
tions.5,13 Medication such as nicotine replacement therapy (NRT), 
varenicline, bupropion, cytosine, and behavioral support increases 
success of quit attempts in the general population of smokers, partic-
ularly when combined14–18 and have been recommended as effective 
interventions within clinical guidelines for the general population.19 
Clinical guidelines for substance use services20 state that “Secondary 
care providers have a duty of care to protect the health of, and pro-
mote healthy behaviour among, people who use, their services. This 
duty of care includes providing effective support to stop smoking or 
abstain from smoking while using secondary care services” (pp.5–6). 
Smokers should be identified at the first opportunity and provided 
with advice and support.19 This includes providing pharmacother-
apy to support abstinence along with an offer of arranging intensive 
behavioral support. Common assumptions include that the level of 
motivation to quit within patients with substance use disorders is 
low; however, it has been found that patients receiving treatment 
for substance use disorders are as motivated to quit as smokers in 
the general population.6,21,22 A further concern is that tobacco cessa-
tion will compromise substance use treatment, however a previous 
review indicates that smoking cessation improves abstinence from 
alcohol and illicit drugs.11
This review aimed to evaluate two main questions: (1) what is 
the effectiveness of different smoking cessation interventions for 
patients with substance use disorders? and (2) what is the impact 
of smoking cessation treatment on substance use outcomes? This 
extends and updates the findings of a previous meta-analysis.11 
The quality of included studies was also evaluated. As many 
substance use disorder services do not offer smoking cessation 
treatment,23 it is hoped that the findings will provide a clearer 
direction of how to incorporate smoking cessation into substance 
use treatment.
Methods
Search Strategy
Searches were conducted by SLT in February 2014 and updated in 
August 2014. Included literature was published from 1990 onwards. 
Databases searched were Cinahl, Medline, Psycharticles, Psychbooks, 
Centre for Reviews and Dissertations, British Library, Web of Science, 
Science Direct, The Cochrane Library, and Swetswise. The search 
strategy included searching for grey literature using Open Grey, 
Grey Net, The Medical Research Council, Ethos (British Library), 
The Universal Index of Doctoral Dissertations, and The Conference 
Proceedings Citation Index. Words relating to smoking cessation and 
substance use disorders, using combinations of “or” and “and” or 
free text were adapted as required for each database. The thesaurus 
and MeSH terms were used to identify associated search terms. The 
final list of search terms is provided as a Supplementary Material S1.
To identify any additional studies of relevance to the research 
questions, a search was conducted in the Journal of Substance Abuse 
Treatment, Drug and Alcohol Dependence, Addictive Behaviours, 
and Addiction for editions between January 2010 and January 2014 
as these journals had published the majority of the papers identified 
for review. Manual searches of reference lists and citation searches 
were also completed.
Inclusion and Exclusion Criteria
To review the most methodologically sound studies, only rand-
omized controlled trials of smoking cessation interventions with 
at least 6 months follow-up, involving smokers over the age of 18, 
who had recently completed or were currently receiving inpatient 
or outpatient treatment for a substance use disorder (drugs or alco-
hol) were included. Interventions could include pharmacological and 
nonpharmacological approaches in any setting and mode of delivery. 
Trials had to include two different treatments, one of which could 
be placebo or usual care. Trials comparing different timings such 
as concurrent versus delayed implementation of the same interven-
tion were therefore excluded. The question of timing is the subject 
of a proposed Cochrane review.24 In addition, studies had to report 
biochemically-verified smoking abstinence outcomes in accordance 
with the Russell Standard.25
Outcome Measures
The primary outcome measure was biochemically verified (carbon 
monoxide) self-reported continuous abstinence from smoking, at 
the 6- or 12-month follow-up.25,26 Secondary outcome measures 
were biochemically verified self-reported 7-day point prevalence 
abstinence from smoking (PPA) at 6- or 12-month follow-up.25,27 
Substance use treatment outcomes at 6 or 12  months were also 
included. Different studies reported different substance use treat-
ment outcomes. Three studies defined substance use abstinence as 
self-reported, no substance use over the last week confirmed by 
urine drug screen or breath alcohol test results.28–30 Two studies 
defined 30-day point prevalence substance use abstinence as self-
reported, no substance use during the 30 days prior to follow-up 
combined with a breath alcohol test31 or a breath alcohol and a 
urine drug screen.32 One study defined continuous substance use 
abstinence as self-reported, no substance use over the 90 days prior 
to the follow-up time point confirmed by urine drug screen or 
breath alcohol test results.33 One study defined the proportion of 
heavy drinking days as the amount of heavy drinking days, 14 days 
prior follow-up and the 30 days prior to the 3- and 6-month fol-
low-up. A heavy drinking day was defined as any day on which a 
man drank six or more standard drinks, or a woman drank four or 
more standard drinks.34 Because little evidence on the effectiveness 
of interventions in this population is available, for studies reporting 
no effect at 6 or 12  months, earlier follow-up comparisons were 
included as secondary outcomes.
Data Analysis
SLT screened the initial titles. SLT and LSB screened the abstracts 
and full papers for relevance to the research question. Reasons 
for exclusion were documented and any discrepancies discussed 
amongst the reviewers to arrive at a consensus (excluded references 
in Supplementary Table S2).
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Data extraction was carried out by SLT and LSB using a data 
extraction sheet designed for randomized controlled trials.35 The 
data extraction process recorded the following: study aims, popula-
tion, eligibility criteria, randomization methods, sample characteris-
tics, intervention type, study setting, recruitment method, study staff, 
substance type, smoking and substance use outcomes measures, fol-
low-up period, and study findings. There was a 95% agreement rate 
between reviewers and disagreements were resolved through discus-
sion and rechecking the papers. Quality assessment was carried out 
by SLT and LSB using the Cochrane tool for assessing bias.35 Where 
statistical information was available from the paper or by contact-
ing the author, findings were computed into a common effect size 
statistic of r.36
Due to heterogeneity in terms of the population, control group, 
length of follow-up and outcome measures, there were no sets of 
studies that were sufficiently similar to make them suitable for inclu-
sion in a meta-analysis, so a narrative synthesis was used.
Results
The screening process led to the identification of 17 studies for inclu-
sion in the review. Figure 1 contains a flow diagram37 of the screen-
ing process. Study characteristics are summarized in Table 1. Study 
sample size ranged from 64 to 383 participants. Mean age of the 
participants ranged from 34 years to 50 years. One study contained 
100% males, otherwise the percentage of males ranged from 50% 
to 97%. Mean baseline number of cigarettes smoked per day ranged 
from 16 to 32.
Eight studies investigated smoking cessation in alcohol treatment 
only, five investigated alcohol and drug treatment and four inves-
tigated drug treatment only. Studies included one or more of the 
following addictive substances: alcohol, cocaine, heroin, cannabis, 
amphetamines, methamphetamines, and benzodiazepines.
Treatment Status
Five studies investigated smokers currently in treatment for a sub-
stance use disorder. Four studies stated that patients were currently 
in treatment but enrolled in the intervention after a specific period 
of abstinence (eg, 7 days abstinence38, after 30 days abstinence30,32 or 
had a substance use diagnosis in the past 3 months49). Three stud-
ies investigated methadone-maintained patients. Five of the studies 
investigated smokers with a past history or drug or alcohol abuse. 
This tended to relate to a specific period of abstinence (eg, at least 
2 months abstinence,41 between 2 and 12 months abstinence42 or at 
least 1 year of abstinence39). One study stated that participants had 
an average of 4  years abstinence43 and another study participants 
had a median of 5 years of abstinence.40
Interventions
Setting
Twelve studies were conducted in outpatient and five in inpatient 
settings. Intervention settings included long-term and short-term 
residential treatment, outpatient community treatment centers, and 
outpatient methadone clinics.
Recruitment Method
Six studies reported recruitment methods, including advertisements 
in local newspapers or on clinic bulletin boards and asking people 
to contact the research team to take part. Other methods included 
recruiting patients through nominations from treatment staff. 
Three studies used Alcoholics Anonymous (AA) meetings as a way 
to recruit patients, including one study which appointed members 
of the AA group as study recruiters. One study gave presentations 
at treatment clinics until enough patients had enrolled. Overall, 
12 studies either required participants to have an intention to quit 
smoking or recruited participants via posters or other advertising, 
Studies identified through search 
strategy (n=847)
Records screened (n=717)
Full text articles assessed for 
eligibility (n=59) Studies excluded (n=42)
- No smoking intervention=11
- Not a RCT= 9
- Not main study=8
- Short follow-up period=5
- One intervention, Concurrent 
vs delayed= 5
- Abstinence measure= 4
Studies excluded (n=491)
Duplicate studies removed (n=130)
Studies excluded (n=167)
Abstracts screened (n= 226)
Studies included in review (n=17)
Figure 1. Search process and study selection.
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suggesting that participants were likely to have had some intention 
or motivation to quit.
Smoking Outcome Measures
One study reported only continuous abstinence at 6 months, another 
at 6- and 12-month follow-up. Four studies reported continuous 
abstinence and PPA: two at 6 months, one at 6 and 12 months and 
one at 12 months. Eleven studies only measured PPA, as the primary 
smoking outcome; of these, seven studies reported smoking out-
comes at 6 months only, three studies reported smoking outcomes at 
6 and 12 months and one reported smoking outcomes at 12 months.
Intervention Characteristics
The intervention characteristics can be seen in Supplementary Table 
S3. The studies used a variety of different staff members to deliver 
the interventions, including research staff, therapists, nurses, physi-
cians, and psychiatrists. The main intervention categories included 
counseling only; counseling and NRT; NRT only; cognitive behavio-
ral treatment (CBT) only; CBT and NRT; motivational interviewing; 
bupropion and varenicline. One approach, used in three of the inter-
ventions32,45,48 was contingency management (CM) which involves 
positive reinforcement (use of financial or material incentive) to pro-
mote desired behaviors.50
Effectiveness of Smoking Cessation Interventions
Five of the 17 studies reported significant effects at 6- or 12-month 
follow-up. One study40 found significant differences in continuous 
abstinence at 6 months, another study33 found significant differences 
in continuous abstinence at 12 but not at 6 months and a further 
study found significant differences in continuous abstinence at both 
6 and 12  months.32 Two studies reporting PPA as primary out-
come31,48 found significant differences between interventions, both at 
6 months. Four of the studies provided smoking cessation treatment 
concurrently with substance use treatment and one provided treat-
ment for patients with a past history of a substance use disorder. 
Results are detailed in Supplementary Table S3.
Two studies found evidence that NRT is of benefit.33,40 For out-
patient smokers with a past history of alcohol dependence, 21-mg 
nicotine patches significantly increased continuous abstinence at 
4 months and at 6 months compared with a placebo patch.40 A com-
bination of CBT, nicotine patch and nicotine gum had significantly 
higher continuous abstinence rates at 12 months than the CBT, nico-
tine patch and placebo gum condition33 for outpatient smokers in 
early treatment for alcohol dependence.
One study found evidence that a behavioral support is of benefit.32 
A multicomponent smoking treatment (MST) consisting of 5 weeks 
of prequit treatment, 4 weeks of postquit counseling, individual daily 
counseling sessions, contingency contracting, and relapse prevention 
training was compared against the same MST plus generalization 
training (MST+G), and a usual care condition32 for inpatient, newly 
recovering drug and alcohol dependent smokers. All participants 
received nicotine patches. The relapse prevention training identified 
high risk situations and practiced coping skills that could be used 
in these situations. The generalization training similarly identified 
high risk situations common to smoking, drug and alcohol use, and 
involved practicing coping skills to prevent relapse to all substances. 
Continuous abstinence differed significantly between groups both at 
6 and 12 months, with both intervention groups achieving higher 
rates than the usual care group. There were no significant differences 
in PPA at the 6-month or at 12-month follow-up; although the two Ta
b
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intervention groups combined and separately had higher than the 
usual care group at 1-month postquit.
Two studies found evidence that a combination of behavioral 
support and medication was beneficial to smoking cessation.31,48 
Carmody31 provided an intensive intervention consisting of 16 ses-
sions of individualized CBT, 16 weeks of nicotine patches and 26 
weeks of nicotine lozenges in comparison with usual care which 
included a referral to a smoking cessation clinic. PPA was signifi-
cantly higher for the intensive intervention group at 12 weeks for 
outpatient alcohol dependent smokers in early recovery and at 
6  months but there was no significant difference at 12  months. 
Winhusen48 randomized outpatient, current stimulant dependent 
smokers into substance use treatment as usual or substance use treat-
ment as usual plus smoking cessation treatment. Smoking cessation 
treatment included weekly individualized counseling and bupropion. 
Further into the intervention, participants were also offered a nico-
tine inhaler and CM. PPA was significantly higher in the interven-
tion group compared to the treatment as usual group at 10 weeks, 
3 months, and at 6-month follow-up.
Of the 12 studies that did not find treatment effective at 6 or 
12 months, four observed significant effects at shorter term follow-
ups. During one study45 all participants received 12 weeks of nico-
tine patches and were assigned to one of four conditions: patch only, 
relapse prevention plus patch, CM plus patch and relapse preven-
tion, or CM plus patch. At 12 weeks, participants assigned to receive 
CM showed statistically higher rates of PPA than those not assigned 
to receive contingencies.
Another intervention30 randomized outpatient smokers from a 
drug and alcohol dependence treatment program to counseling plus 
NRT or substance use treatment as usual. The PPA rates were signifi-
cantly higher in the smoking cessation condition rather than treat-
ment as usual, during week 2–7 but not at 6-month follow-up.
When comparing a brief 15-minute counseling session with 
three intensive 60-minute individual sessions and 8 weeks of nico-
tine patches, PPA was significantly higher for the intensive condition 
(27.5%) than the brief condition (6.6%) at 1 month postquit date but 
not at 6-month follow-up for outpatient alcohol dependent smokers.49
Finally, Patten and colleagues43 compared counseling plus nico-
tine gum, counseling plus physical exercise and a standard treatment 
condition for outpatient heavy smokers recovering from alcohol 
dependence. Short term differences in PPA rates between interven-
tions were significant at posttreatment, with higher quit rates in the 
counseling plus physical exercise condition (60%) compared with 
standard condition (31%).
For the eight studies where no evidence of effectiveness was 
found, interventions involved counseling,28 NRT,41 CBT,29 moti-
vational interviewing,44 bupropion,39,42 varenicline,47 and a com-
bination of treatments.46 In relation to inpatient versus outpatient 
settings, one of the five inpatient studies found significant effects 
compared with eight of the 12 outpatient studies.
Effects on Substance Use Outcomes
Ten of the 17 studies reported the impact of smoking cessation inter-
ventions on substance use outcomes. Two of these studies reported 
a difference in substance use outcomes across conditions. The drug 
and alcohol abstinence rates were higher in the MST condition 
rather than the MST+G condition at 6- and at 12-month follow-
up,33 although neither differed significantly from that of the usual 
care condition (figures not reported in article). There was also a sig-
nificant difference in drug and alcohol relapse rates between MST 
and MST+G conditions suggesting that participants in the MST 
condition had lower relapse rates than those in the MST+G condi-
tion. In the Shoptaw study described above,45 during weeks where 
patients with substance use disorders met the criteria for smoking 
abstinence they also provided more opiate and cocaine-free urine 
samples. The remaining eight studies did not find any significant dif-
ference between conditions in relation to substance use outcomes.
Quality Review
Overall, many of the details required to determine quality were not 
reported (Table 2). Only eight studies reported sufficient information 
on randomization and three provided adequate information on allo-
cation concealment. Nine studies reported adequate information on 
blinding of participants or investigators and seven reported adequate 
information on blinding of outcome assessors. Thirteen studies used 
intention to treat analysis51 where all randomized patients were 
included in their originally assigned groups and missing data was 
recorded as non-abstinence.
Two studies had a high risk of reporting fewer outcomes than 
expected or not reporting the use of a protocol. Only five stud-
ies reported carrying out power analysis in sufficient detail within 
the article with all stating that they sought a power of at least .80. 
Effect sizes36 could only be calculated for 12 of the studies where the 
required information was reported. Of the studies with a significant 
effect, two studies31,48 had effect sizes between r =  .17 and r =  .19 
and another had r = .27.33 Two studies had effect sizes32,40 between 
r = .32 and r = .47. Three studies without a significant effect at long 
term follow-up30,43,46 had effect sizes r < .1, three had effect sizes 
between r = .10 and r = .19.28,47,49
Discussion
Seventeen randomized controlled trials investigating the effective-
ness of smoking cessation interventions, for patients with substance 
use disorders were identified for inclusion in this review. Five studies 
reported significant effects on smoking cessation, providing evidence 
of effectiveness of NRT, behavioral support and combinations of the 
two, although not all trials testing combination treatments found an 
effect. Four other studies reported significant intervention effects at 
shorter follow-ups but not at the required 6 or 12 months, providing 
weaker evidence to support the effectiveness of NRT, combinations 
of NRT and behavioral support, as well as some suggestion that CM 
and physical activity may be beneficial. Two studies showed some 
evidence of improved substance use outcomes. They had in common 
that the smoking cessation interventions provided a combination of 
CM and relapse prevention. None of the trials suggested a negative 
effect of smoking cessation treatment on substance use outcomes.
Weaknesses in methods and reporting in some cases, combined 
with the small number of studies make the conclusion about the 
effectiveness of these interventions tentative. Many papers did not 
clearly state how the trials protected against bias, as indicated by the 
high proportion categorized as “unclear risk.”52,53 Only five studies 
reported carrying out a power analysis prospectively to determine 
sample size and it is particularly important to allow for attrition 
when treating patients with substance use disorders. When calcu-
lated, studies reporting significant differences had between small 
and medium effect sizes.36 Five of the nonsignificant results had very 
small effect sizes (<0.1) and would have required a much larger sam-
ple size (>700 participants) to achieve adequate power. Alternatively, 
a more intensive design or longer treatment may have produced 
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stronger effects. None of the studies provided an economic evalua-
tion of the interventions, which is an important factor in determining 
optimal treatment.
Meta-analysis could not be conducted due to the heterogeneity 
in the studies including the design, follow-up period and treatment 
lengths. Due to this we were not able to combine the effect sizes and 
probabilities found in the studies or combine results of studies to 
increase the power of statistical tests.54
Strengths of this review include that it concentrated on rand-
omized controlled trials. This was due to the volume of study designs 
in this area and the aim of reviewing the most methodologically sound 
studies. Also, an established quality rating scale35 was used for data 
extraction and was completed independently by two authors to mini-
mize any rating errors. The risk of publication bias was minimized 
through the use of several search mechanisms which strengthen the 
search strategy. The broad search strategy gives confidence that all 
currently available evidence has been identified in this review.
These findings update and extend previous review findings as 13 
of the studies were conducted between 2003 and 2014 since the last 
meta-analysis was carried out.11 This review provides further descrip-
tions of interventions and control conditions as well as recruitment 
methods, study staff, setting and treatment length to characteristics 
of a variety of treatment approaches.
NRT and behavioral support and combinations were effective in 
this population, which is in line with findings in the general popu-
lation17,18,55,56 and the recommendations of the previous review for 
patients with substance use disorders.11 Varenicline was not found to 
be effective in one trial, which is different from the general popula-
tion, where it has been found to be one of the most effective medica-
tions.57 We also found no evidence for the effectiveness of bupropion, 
which is effective in the general population,58 although again, there 
was only two trials investigating this in a substance use population.
Future research should include additional studies of the effective-
ness of varenicline and bupropion for substance use disorder popula-
tions and address the methodological limitations of the studies included 
in this review. The aim should be to identify interventions that promote 
longer term abstinence into the 6- or 12-month follow-up period, using 
a measure of continuous abstinence wherever possible. Sample sizes 
should be planned prospectively to ensure adequate power to identify 
beneficial interventions. Future research should aim to identify which 
specific aspects of the combination treatments have a significant effect 
on smoking outcomes and what effect the mode of delivery or fre-
quency of treatment have on abstinence in this population.
The timing of smoking cessation interventions is an important 
area of research as the question still remains whether smoking ces-
sation treatment should be offered during substance use disorder 
treatment or delayed until treatment is complete.24 We did not test 
this hypothesis in our study but four of the effective studies offered 
concurrent smoking cessation and substance use disorder treatment 
suggesting that concurrent treatment of smoking alongside other 
treatment can be successful.
Barriers to implementing smoking cessation interventions for 
patients with substance use disorders include limited knowledge 
of how to engage this population into treatment and a belief that 
stopping smoking may affect recovery from other substances.59 
Incorporating smoking cessation into substance use disorder treat-
ment gives a clear message that quitting smoking is a major health 
priority. Patients with substance use disorders may require more 
intensive interventions to treat a number of addictions and tobacco 
is often viewed as a less harmful alternative to drugs and alcohol.12 
Besides its addictive properties, cigarette smoking is legal and socially 
acceptable in many settings, giving it greater availability than other 
drugs.60 Treatment providers may need to employ strategies to avoid 
attrition, maintain motivation and make it as easy as possible to 
access the clinic. Modern smoking cessation approaches could be 
investigated; for example, e-cigarettes and mobile apps have yet to 
be tested as interventions in this population although risks and ben-
efits associated with e-cigarette use are still under investigation.
Conclusions
Smoking cessation interventions using NRT, behavioral support and 
combination approaches appear to increase smoking abstinence in 
those treated for substance use disorders and have no effect on other 
Table 2. Quality Review
Selection bias Performance bias Detection bias Attrition bias Reporting bias Sample bias
Author
Random  
sequence 
generation
Allocation 
concealment
Blinding of  
participant and  
personnel
Blinding  
of outcome 
assessment
Incomplete 
outcomes data
Selective  
reporting Power analysis
Burling et al.32 Unclear risk Unclear risk Unclear risk Unclear risk Low risk High risk Not reported
Carmody et al.38 Low risk Unclear risk High risk Unclear risk Unclear risk Low risk Not reported
Cooney et al.34 Low risk Low risk Low risk Low risk Low risk Low risk Not reported
Cooney et al.33 Unclear risk Unclear risk Unclear risk Unclear risk High risk High risk >0.80
Gariti et al.28 Unclear risk Unclear risk Unclear risk Low risk Low risk High risk Not reported
Hays et al.39 Unclear risk Unclear risk Low risk Unclear risk Unclear risk Low risk Not reported
Hughes et al.40 Unclear risk Unclear risk Unclear risk Unclear risk Low risk High risk 0.80
Kalman et al.41 Unclear risk Unclear risk Low risk Low risk Low risk High risk Not reported
Kalman et al.42 Low risk Low risk Low risk High risk Low risk Low risk 0.80
Mueller et al.29 Unclear risk Unclear risk Unclear risk Unclear risk High risk High risk Not reported
Patten et al.43 Unclear risk Unclear risk Unclear risk Unclear risk Low risk High risk Not reported
Reid et al.30 Low risk Unclear risk Low risk Unclear risk Low risk High risk Not reported
Rohsenow et al.44 Low risk Low risk Low risk Low risk Low risk Low risk Not reported
Shoptaw et al.45 Low risk Unclear risk Unclear risk Unclear risk Low risk High risk Not reported
Stein et al.46 Unclear risk Unclear risk Unclear risk Low risk Low risk High risk 0.80
Stein et al.47 Unclear risk Unclear risk Low risk Low risk Low risk Low risk 0.80
Winhusen et al.48 Unclear risk Unclear risk Low risk Unclear risk Low risk High risk Not reported
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substance use treatment outcomes. However, higher quality studies 
and reporting are required to strengthen the evidence base.
Supplementary Material
Supplementary Material S1 and Tables S2 and S3 can be found 
online at http://www.ntr.oxfordjournals.org
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